as 11-15-2024 4:00pm EST
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 117.1M | IPO Year: | N/A |
Target Price: | $8.63 | AVG Volume (30 days): | 452.0K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.91 | EPS Growth: | N/A |
52 Week Low/High: | $1.55 - $5.00 | Next Earning Date: | 11-13-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
LPTX Breaking Stock News: Dive into LPTX Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
PR Newswire
2 months ago
PR Newswire
3 months ago
The Telegraph
5 months ago
Simply Wall St.
5 months ago
Simply Wall St.
5 months ago
Simply Wall St.
5 months ago
Motley Fool
5 months ago
The information presented on this page, "LPTX Leap Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.